Advertisement
BLK vs CNS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BLK is a StrongBuy and CNS is a StrongBuy.
BLK in upward trend: 10-day moving average moved above 50-day moving average on October 22, 2026
The 10-day moving average for BLK crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on BLK as a result. In 43 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for BLK just turned positive on September 25, 2026. Looking at past instances where BLK's MACD turned positive, the stock continued to rise in 24 of 46 cases over the following month. The odds of a continued upward trend are 52%.
BLK moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLK advanced for three days, in 194 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 143 of 293 cases where BLK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.
Bearish Trend Analysis
The 10-day RSI Indicator for BLK moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 19 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
BLK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 29 (best 1 - 100 worst), indicating outstanding price growth. BLK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 49 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 63 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.090) is normal, around the industry mean (2.404). P/E Ratio (27.126) is within average values for comparable stocks, (-3.413). Projected Growth (PEG Ratio) (0.898) is also within normal values, averaging (1.319). Dividend Yield (0.020) settles around the average of (0.272) among similar stocks. P/S Ratio (6.270) is also within normal values, averaging (15.798).
CNS's RSI Indicator ascending out of oversold territory
The RSI Oscillator for CNS moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 18 of the 24 cases the stock moved higher. This puts the odds of a move higher at 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on CNS as a result. In 54 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for CNS just turned positive on October 20, 2026. Looking at past instances where CNS's MACD turned positive, the stock continued to rise in 30 of 47 cases over the following month. The odds of a continued upward trend are 64%.
Following a +4.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNS advanced for three days, in 182 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
CNS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
The Aroon Indicator for CNS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. CNS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.130) is normal, around the industry mean (2.404). P/E Ratio (21.486) is within average values for comparable stocks, (-3.413). Projected Growth (PEG Ratio) (1.671) is also within normal values, averaging (1.319). Dividend Yield (0.038) settles around the average of (0.272) among similar stocks. P/S Ratio (6.139) is also within normal values, averaging (15.798).
The Tickeron Profit vs. Risk Rating rating for this company is 99 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
BLK | CNS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 47 | 99 | |
SMR RATING 1..100 | 63 | 33 | |
PRICE GROWTH RATING 1..100 | 29 | 59 | |
P/E GROWTH RATING 1..100 | 49 | 45 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BLK's Valuation (90) in the Investment Managers industry is in the same range as CNS (93). This means that BLK’s stock grew similarly to CNS’s over the last 12 months.
BLK's Profit vs Risk Rating (47) in the Investment Managers industry is somewhat better than the same rating for CNS (99). This means that BLK’s stock grew somewhat faster than CNS’s over the last 12 months.
CNS's SMR Rating (33) in the Investment Managers industry is in the same range as BLK (63). This means that CNS’s stock grew similarly to BLK’s over the last 12 months.
BLK's Price Growth Rating (29) in the Investment Managers industry is in the same range as CNS (59). This means that BLK’s stock grew similarly to CNS’s over the last 12 months.
CNS's P/E Growth Rating (45) in the Investment Managers industry is in the same range as BLK (49). This means that CNS’s stock grew similarly to BLK’s over the last 12 months.
| BLK | CNS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 53% | 1 day ago 75% |
| Stochastic ODDS (%) | 1 day ago 60% | 1 day ago 63% |
| Momentum ODDS (%) | 1 day ago 57% | 1 day ago 64% |
| MACD ODDS (%) | 1 day ago 52% | 1 day ago 64% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 60% |
| TrendMonth ODDS (%) | 1 day ago 60% | 1 day ago 68% |
| Advances ODDS (%) | 2 days ago 57% | 7 days ago 60% |
| Declines ODDS (%) | 15 days ago 56% | 9 days ago 67% |
| BollingerBands ODDS (%) | 1 day ago 50% | 1 day ago 64% |
| Aroon ODDS (%) | 1 day ago 49% | 1 day ago 68% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BLK’s FA Score shows that 1 FA rating(s) are green while CNS’s FA Score has 1 green FA rating(s).
- BLK’s FA Score: 1 green, 4 red.
- CNS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BLK’s TA Score shows that 6 TA indicator(s) are bullish while CNS’s TA Score has 5 bullish TA indicator(s).
- BLK’s TA Score: 6 bullish, 4 bearish.
- CNS’s TA Score: 5 bullish, 3 bearish.
Price Growth
BLK (@Investment Managers) experienced а +1.47% price change this week, while CNS (@Investment Managers) price change was +5.83% for the same time period.
The average weekly price growth across all stocks in the @Investment Managers industry was -1.39%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -0.93%.
Reported Earning Dates
BLK is expected to report earnings on Jan 21, 2027.
CNS is expected to report earnings on Jan 27, 2027.
Industries' Descriptions
@Investment Managers (-1.39% weekly)Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.
Advertisement
CNS and
Correlation & Price change
A.I.dvisor indicates that over the last year, CNS has been loosely correlated with BAM. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CNS jumps, then BAM could also see price increases.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DFNM | 46.93 | 0.26 | +0.56% |
| Dimensional National Municipal Bond ETF (DFNM) | |||
| ABOT | 45.50 | N/A | N/A |
| Abacus FCF Innovation Leaders ETF (ABOT) | |||
| DECT | 40.43 | -0.40 | -0.98% |
| AllianzIM U.S. Equity Buffer10 Dec ETF (DECT) | |||
| DUBS | 42.92 | -0.55 | -1.26% |
| Aptus Large Cap Enhanced Yield ETF (DUBS) | |||
| BALQ | 54.06 | -1.80 | -3.23% |
| iShares Nasdaq Premium Income Active ETF (BALQ) | |||